The results of the present study showed a significant tumor-associated increase of IL-4 when comparing patients with HNSCC and controls (P=0.0001), but unlike Mojtahedi et al (17), a significant decrease of IL-4 post-therapeutic (P=0.8500) was not found. This evidence concerns the gene IL4 and neoplasm.